Brought to you by 
Mylan licenses six biosimilars from Momenta; Momenta changes course and only moves forward with one
09 Nov 2021
Executive Summary
Momenta Pharmaceuticals Inc. granted Mylan NV global rights to develop, manufacture, and sell six of its biosimilars in development. The only candidate disclosed was M834, a biosimilar to the rheumatoid arthritis drug Orencia (abatacept).
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Mylan licenses six biosimilars from Momenta; Momenta changes course and only moves forward with one
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice